Cybin Inc. (HELP) Discusses Phase II Results for HLP004 in Generalized Anxiety Disorder - Slideshow

Cybin Inc. presented Phase II clinical trial results for HLP004, its deuterated psilocybin analog, targeting generalized anxiety disorder (GAD) in March 2026. The trial demonstrated statistically significant reductions in anxiety symptoms compared to placebo, meeting its primary endpoint with a favorable safety profile and no serious adverse events reported. HLP004 uses proprietary deuteration technology to optimize psilocybin’s pharmacokinetic properties, potentially improving durability and reducing side effects versus traditional psychedelics. Data suggests rapid onset of therapeutic effects, with sustained benefits observed at four-week follow-ups, aligning with growing interest in psychedelic-assisted mental health therapies. Investor and clinical focus now shifts to Phase III trials, with Cybin positioning HLP004 as a potential breakthrough for treatment-resistant GAD.